nodes	percent_of_prediction	percent_of_DWPC	metapath
Nelfinavir—CYP3A4—bone cancer	0.4	1	CbGaD
Nelfinavir—ABCG2—Carboplatin—bone cancer	0.0678	0.148	CbGbCtD
Nelfinavir—ABCG2—Cisplatin—bone cancer	0.0579	0.126	CbGbCtD
Nelfinavir—SLCO1A2—Methotrexate—bone cancer	0.0502	0.109	CbGbCtD
Nelfinavir—SLCO1B1—Methotrexate—bone cancer	0.0473	0.103	CbGbCtD
Nelfinavir—CYP2B6—Cisplatin—bone cancer	0.0407	0.0887	CbGbCtD
Nelfinavir—ABCG2—Doxorubicin—bone cancer	0.0388	0.0845	CbGbCtD
Nelfinavir—ABCG2—Methotrexate—bone cancer	0.0376	0.0819	CbGbCtD
Nelfinavir—CYP2B6—Doxorubicin—bone cancer	0.0273	0.0594	CbGbCtD
Nelfinavir—CYP2C9—Cisplatin—bone cancer	0.0215	0.0469	CbGbCtD
Nelfinavir—ABCB1—Cisplatin—bone cancer	0.0209	0.0455	CbGbCtD
Nelfinavir—ABCB1—Doxorubicin—bone cancer	0.014	0.0305	CbGbCtD
Nelfinavir—ABCB1—Methotrexate—bone cancer	0.0136	0.0295	CbGbCtD
Nelfinavir—CYP2D6—Doxorubicin—bone cancer	0.0132	0.0287	CbGbCtD
Nelfinavir—CYP3A4—Doxorubicin—bone cancer	0.00839	0.0183	CbGbCtD
Nelfinavir—Indinavir—CYP3A4—bone cancer	0.00103	0.573	CrCbGaD
Nelfinavir—Saquinavir—CYP3A4—bone cancer	0.00077	0.427	CrCbGaD
Nelfinavir—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000727	0.0135	CbGpPWpGaD
Nelfinavir—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.000727	0.0135	CbGpPWpGaD
Nelfinavir—CYP3A7—Xenobiotics—CYP3A4—bone cancer	0.000721	0.0134	CbGpPWpGaD
Nelfinavir—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000693	0.0129	CbGpPWpGaD
Nelfinavir—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00065	0.0121	CbGpPWpGaD
Nelfinavir—CYP3A7—Metapathway biotransformation—CYP4V2—bone cancer	0.000643	0.012	CbGpPWpGaD
Nelfinavir—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000597	0.0111	CbGpPWpGaD
Nelfinavir—ABCG2—Fluoropyrimidine Activity—DHFR—bone cancer	0.000575	0.0107	CbGpPWpGaD
Nelfinavir—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000543	0.0101	CbGpPWpGaD
Nelfinavir—CYP2B6—Xenobiotics—CYP3A4—bone cancer	0.000533	0.00993	CbGpPWpGaD
Nelfinavir—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000521	0.0097	CbGpPWpGaD
Nelfinavir—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000502	0.00935	CbGpPWpGaD
Nelfinavir—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000501	0.00933	CbGpPWpGaD
Nelfinavir—CYP2B6—Metapathway biotransformation—CYP4V2—bone cancer	0.000475	0.00885	CbGpPWpGaD
Nelfinavir—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000472	0.00879	CbGpPWpGaD
Nelfinavir—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000465	0.00865	CbGpPWpGaD
Nelfinavir—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000448	0.00834	CbGpPWpGaD
Nelfinavir—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000443	0.00825	CbGpPWpGaD
Nelfinavir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00044	0.0082	CbGpPWpGaD
Nelfinavir—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000411	0.00766	CbGpPWpGaD
Nelfinavir—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000403	0.0075	CbGpPWpGaD
Nelfinavir—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000387	0.00721	CbGpPWpGaD
Nelfinavir—Malnutrition—Cisplatin—bone cancer	0.000386	0.00453	CcSEcCtD
Nelfinavir—Erythema—Cisplatin—bone cancer	0.000386	0.00453	CcSEcCtD
Nelfinavir—Rash maculo-papular—Doxorubicin—bone cancer	0.000382	0.00448	CcSEcCtD
Nelfinavir—Flatulence—Cisplatin—bone cancer	0.000381	0.00447	CcSEcCtD
Nelfinavir—Mouth ulceration—Doxorubicin—bone cancer	0.00038	0.00445	CcSEcCtD
Nelfinavir—Diabetes mellitus—Epirubicin—bone cancer	0.000379	0.00444	CcSEcCtD
Nelfinavir—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000375	0.00699	CbGpPWpGaD
Nelfinavir—Muscle spasms—Cisplatin—bone cancer	0.000371	0.00436	CcSEcCtD
Nelfinavir—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.00037	0.0069	CbGpPWpGaD
Nelfinavir—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000367	0.00684	CbGpPWpGaD
Nelfinavir—CYP2B6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000366	0.00682	CbGpPWpGaD
Nelfinavir—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000359	0.00669	CbGpPWpGaD
Nelfinavir—Ill-defined disorder—Cisplatin—bone cancer	0.000358	0.00421	CcSEcCtD
Nelfinavir—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000358	0.00666	CbGpPWpGaD
Nelfinavir—Anaemia—Cisplatin—bone cancer	0.000357	0.00419	CcSEcCtD
Nelfinavir—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000356	0.00664	CbGpPWpGaD
Nelfinavir—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000353	0.00658	CbGpPWpGaD
Nelfinavir—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000351	0.00654	CbGpPWpGaD
Nelfinavir—Diabetes mellitus—Doxorubicin—bone cancer	0.00035	0.00411	CcSEcCtD
Nelfinavir—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000349	0.00649	CbGpPWpGaD
Nelfinavir—Malaise—Cisplatin—bone cancer	0.000348	0.00409	CcSEcCtD
Nelfinavir—Leukopenia—Cisplatin—bone cancer	0.000346	0.00406	CcSEcCtD
Nelfinavir—Dermatitis bullous—Epirubicin—bone cancer	0.000345	0.00404	CcSEcCtD
Nelfinavir—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000341	0.00636	CbGpPWpGaD
Nelfinavir—Hypoglycaemia—Epirubicin—bone cancer	0.000337	0.00396	CcSEcCtD
Nelfinavir—Convulsion—Cisplatin—bone cancer	0.000335	0.00393	CcSEcCtD
Nelfinavir—Mood swings—Methotrexate—bone cancer	0.000333	0.00391	CcSEcCtD
Nelfinavir—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.00033	0.00615	CbGpPWpGaD
Nelfinavir—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.000329	0.00387	CcSEcCtD
Nelfinavir—Myalgia—Cisplatin—bone cancer	0.000329	0.00386	CcSEcCtD
Nelfinavir—Anxiety—Cisplatin—bone cancer	0.000328	0.00385	CcSEcCtD
Nelfinavir—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000327	0.0061	CbGpPWpGaD
Nelfinavir—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000327	0.00609	CbGpPWpGaD
Nelfinavir—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000327	0.00383	CcSEcCtD
Nelfinavir—Liver function test abnormal—Methotrexate—bone cancer	0.000325	0.00381	CcSEcCtD
Nelfinavir—Discomfort—Cisplatin—bone cancer	0.000325	0.00381	CcSEcCtD
Nelfinavir—Affect lability—Epirubicin—bone cancer	0.000324	0.0038	CcSEcCtD
Nelfinavir—Migraine—Epirubicin—bone cancer	0.000324	0.0038	CcSEcCtD
Nelfinavir—Dermatitis bullous—Doxorubicin—bone cancer	0.000319	0.00374	CcSEcCtD
Nelfinavir—Oedema—Cisplatin—bone cancer	0.000315	0.0037	CcSEcCtD
Nelfinavir—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000314	0.00584	CbGpPWpGaD
Nelfinavir—Hypoglycaemia—Doxorubicin—bone cancer	0.000312	0.00366	CcSEcCtD
Nelfinavir—Mood swings—Epirubicin—bone cancer	0.000312	0.00366	CcSEcCtD
Nelfinavir—Thrombocytopenia—Cisplatin—bone cancer	0.000309	0.00362	CcSEcCtD
Nelfinavir—Dehydration—Epirubicin—bone cancer	0.000306	0.00359	CcSEcCtD
Nelfinavir—Skin disorder—Cisplatin—bone cancer	0.000306	0.00359	CcSEcCtD
Nelfinavir—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000305	0.00358	CcSEcCtD
Nelfinavir—Hyperhidrosis—Cisplatin—bone cancer	0.000305	0.00358	CcSEcCtD
Nelfinavir—Liver function test abnormal—Epirubicin—bone cancer	0.000304	0.00357	CcSEcCtD
Nelfinavir—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000302	0.00562	CbGpPWpGaD
Nelfinavir—Abdominal pain upper—Epirubicin—bone cancer	0.000301	0.00353	CcSEcCtD
Nelfinavir—Anorexia—Cisplatin—bone cancer	0.0003	0.00353	CcSEcCtD
Nelfinavir—Affect lability—Doxorubicin—bone cancer	0.0003	0.00352	CcSEcCtD
Nelfinavir—Migraine—Doxorubicin—bone cancer	0.0003	0.00352	CcSEcCtD
Nelfinavir—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000299	0.00557	CbGpPWpGaD
Nelfinavir—Pancreatitis—Methotrexate—bone cancer	0.000298	0.0035	CcSEcCtD
Nelfinavir—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000297	0.00348	CcSEcCtD
Nelfinavir—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000295	0.0055	CbGpPWpGaD
Nelfinavir—Muscular weakness—Epirubicin—bone cancer	0.00029	0.00341	CcSEcCtD
Nelfinavir—Alanine aminotransferase increased—Epirubicin—bone cancer	0.00029	0.00341	CcSEcCtD
Nelfinavir—Mood swings—Doxorubicin—bone cancer	0.000289	0.00339	CcSEcCtD
Nelfinavir—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000287	0.00337	CcSEcCtD
Nelfinavir—Abdominal distension—Epirubicin—bone cancer	0.000287	0.00336	CcSEcCtD
Nelfinavir—Neutropenia—Methotrexate—bone cancer	0.000284	0.00334	CcSEcCtD
Nelfinavir—Dehydration—Doxorubicin—bone cancer	0.000283	0.00333	CcSEcCtD
Nelfinavir—Paraesthesia—Cisplatin—bone cancer	0.000283	0.00332	CcSEcCtD
Nelfinavir—Liver function test abnormal—Doxorubicin—bone cancer	0.000281	0.0033	CcSEcCtD
Nelfinavir—Dyspnoea—Cisplatin—bone cancer	0.000281	0.0033	CcSEcCtD
Nelfinavir—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.00028	0.00521	CbGpPWpGaD
Nelfinavir—Pancreatitis—Epirubicin—bone cancer	0.000279	0.00328	CcSEcCtD
Nelfinavir—Abdominal pain upper—Doxorubicin—bone cancer	0.000278	0.00327	CcSEcCtD
Nelfinavir—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000277	0.00515	CbGpPWpGaD
Nelfinavir—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000274	0.00322	CcSEcCtD
Nelfinavir—Decreased appetite—Cisplatin—bone cancer	0.000274	0.00322	CcSEcCtD
Nelfinavir—Pneumonia—Methotrexate—bone cancer	0.000273	0.0032	CcSEcCtD
Nelfinavir—Gastrointestinal disorder—Cisplatin—bone cancer	0.000272	0.00319	CcSEcCtD
Nelfinavir—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000271	0.00505	CbGpPWpGaD
Nelfinavir—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00027	0.00503	CbGpPWpGaD
Nelfinavir—Pain—Cisplatin—bone cancer	0.00027	0.00316	CcSEcCtD
Nelfinavir—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000269	0.00315	CcSEcCtD
Nelfinavir—Muscular weakness—Doxorubicin—bone cancer	0.000269	0.00315	CcSEcCtD
Nelfinavir—Neutropenia—Epirubicin—bone cancer	0.000266	0.00312	CcSEcCtD
Nelfinavir—Abdominal distension—Doxorubicin—bone cancer	0.000265	0.00311	CcSEcCtD
Nelfinavir—Stomatitis—Methotrexate—bone cancer	0.000264	0.0031	CcSEcCtD
Nelfinavir—Sweating—Methotrexate—bone cancer	0.00026	0.00305	CcSEcCtD
Nelfinavir—Feeling abnormal—Cisplatin—bone cancer	0.00026	0.00305	CcSEcCtD
Nelfinavir—Pancreatitis—Doxorubicin—bone cancer	0.000258	0.00303	CcSEcCtD
Nelfinavir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000257	0.00479	CbGpPWpGaD
Nelfinavir—Hyperglycaemia—Epirubicin—bone cancer	0.000257	0.00301	CcSEcCtD
Nelfinavir—Hepatobiliary disease—Methotrexate—bone cancer	0.000257	0.00301	CcSEcCtD
Nelfinavir—Epistaxis—Methotrexate—bone cancer	0.000256	0.003	CcSEcCtD
Nelfinavir—Pneumonia—Epirubicin—bone cancer	0.000255	0.003	CcSEcCtD
Nelfinavir—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000252	0.0047	CbGpPWpGaD
Nelfinavir—Body temperature increased—Cisplatin—bone cancer	0.000249	0.00292	CcSEcCtD
Nelfinavir—Stomatitis—Epirubicin—bone cancer	0.000247	0.0029	CcSEcCtD
Nelfinavir—Jaundice—Epirubicin—bone cancer	0.000247	0.0029	CcSEcCtD
Nelfinavir—Neutropenia—Doxorubicin—bone cancer	0.000246	0.00289	CcSEcCtD
Nelfinavir—Haemoglobin—Methotrexate—bone cancer	0.000245	0.00287	CcSEcCtD
Nelfinavir—Hepatitis—Methotrexate—bone cancer	0.000243	0.00286	CcSEcCtD
Nelfinavir—Haemorrhage—Methotrexate—bone cancer	0.000243	0.00286	CcSEcCtD
Nelfinavir—Sweating—Epirubicin—bone cancer	0.000243	0.00286	CcSEcCtD
Nelfinavir—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000243	0.00452	CbGpPWpGaD
Nelfinavir—Pharyngitis—Methotrexate—bone cancer	0.000242	0.00284	CcSEcCtD
Nelfinavir—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00024	0.00447	CbGpPWpGaD
Nelfinavir—Hepatobiliary disease—Epirubicin—bone cancer	0.00024	0.00282	CcSEcCtD
Nelfinavir—Epistaxis—Epirubicin—bone cancer	0.000239	0.00281	CcSEcCtD
Nelfinavir—Sinusitis—Epirubicin—bone cancer	0.000238	0.00279	CcSEcCtD
Nelfinavir—Hyperglycaemia—Doxorubicin—bone cancer	0.000238	0.00279	CcSEcCtD
Nelfinavir—Pneumonia—Doxorubicin—bone cancer	0.000236	0.00277	CcSEcCtD
Nelfinavir—Hypersensitivity—Cisplatin—bone cancer	0.000232	0.00273	CcSEcCtD
Nelfinavir—Erythema multiforme—Methotrexate—bone cancer	0.00023	0.0027	CcSEcCtD
Nelfinavir—Haemoglobin—Epirubicin—bone cancer	0.000229	0.00269	CcSEcCtD
Nelfinavir—Stomatitis—Doxorubicin—bone cancer	0.000229	0.00269	CcSEcCtD
Nelfinavir—Jaundice—Doxorubicin—bone cancer	0.000229	0.00269	CcSEcCtD
Nelfinavir—Rhinitis—Epirubicin—bone cancer	0.000228	0.00268	CcSEcCtD
Nelfinavir—Haemorrhage—Epirubicin—bone cancer	0.000228	0.00267	CcSEcCtD
Nelfinavir—Hepatitis—Epirubicin—bone cancer	0.000228	0.00267	CcSEcCtD
Nelfinavir—Eye disorder—Methotrexate—bone cancer	0.000228	0.00267	CcSEcCtD
Nelfinavir—Asthenia—Cisplatin—bone cancer	0.000226	0.00265	CcSEcCtD
Nelfinavir—Pharyngitis—Epirubicin—bone cancer	0.000226	0.00265	CcSEcCtD
Nelfinavir—Sweating—Doxorubicin—bone cancer	0.000225	0.00264	CcSEcCtD
Nelfinavir—Connective tissue disorder—Epirubicin—bone cancer	0.000224	0.00263	CcSEcCtD
Nelfinavir—Hepatobiliary disease—Doxorubicin—bone cancer	0.000222	0.00261	CcSEcCtD
Nelfinavir—Epistaxis—Doxorubicin—bone cancer	0.000222	0.0026	CcSEcCtD
Nelfinavir—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000221	0.00412	CbGpPWpGaD
Nelfinavir—Angiopathy—Methotrexate—bone cancer	0.000221	0.00259	CcSEcCtD
Nelfinavir—Sinusitis—Doxorubicin—bone cancer	0.00022	0.00259	CcSEcCtD
Nelfinavir—Immune system disorder—Methotrexate—bone cancer	0.00022	0.00258	CcSEcCtD
Nelfinavir—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000218	0.00407	CbGpPWpGaD
Nelfinavir—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000216	0.00403	CbGpPWpGaD
Nelfinavir—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000216	0.00402	CbGpPWpGaD
Nelfinavir—Diarrhoea—Cisplatin—bone cancer	0.000216	0.00253	CcSEcCtD
Nelfinavir—Erythema multiforme—Epirubicin—bone cancer	0.000215	0.00253	CcSEcCtD
Nelfinavir—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000213	0.00398	CbGpPWpGaD
Nelfinavir—Eye disorder—Epirubicin—bone cancer	0.000213	0.0025	CcSEcCtD
Nelfinavir—Malnutrition—Methotrexate—bone cancer	0.000212	0.00249	CcSEcCtD
Nelfinavir—Erythema—Methotrexate—bone cancer	0.000212	0.00249	CcSEcCtD
Nelfinavir—Haemoglobin—Doxorubicin—bone cancer	0.000212	0.00249	CcSEcCtD
Nelfinavir—Rhinitis—Doxorubicin—bone cancer	0.000211	0.00248	CcSEcCtD
Nelfinavir—Hepatitis—Doxorubicin—bone cancer	0.000211	0.00247	CcSEcCtD
Nelfinavir—Haemorrhage—Doxorubicin—bone cancer	0.000211	0.00247	CcSEcCtD
Nelfinavir—Pharyngitis—Doxorubicin—bone cancer	0.000209	0.00246	CcSEcCtD
Nelfinavir—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000207	0.00386	CbGpPWpGaD
Nelfinavir—Connective tissue disorder—Doxorubicin—bone cancer	0.000207	0.00243	CcSEcCtD
Nelfinavir—Angiopathy—Epirubicin—bone cancer	0.000207	0.00243	CcSEcCtD
Nelfinavir—Immune system disorder—Epirubicin—bone cancer	0.000206	0.00242	CcSEcCtD
Nelfinavir—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000205	0.00382	CbGpPWpGaD
Nelfinavir—Back pain—Methotrexate—bone cancer	0.000205	0.00241	CcSEcCtD
Nelfinavir—Vomiting—Cisplatin—bone cancer	0.0002	0.00235	CcSEcCtD
Nelfinavir—Erythema multiforme—Doxorubicin—bone cancer	0.000199	0.00234	CcSEcCtD
Nelfinavir—Rash—Cisplatin—bone cancer	0.000199	0.00233	CcSEcCtD
Nelfinavir—Dermatitis—Cisplatin—bone cancer	0.000199	0.00233	CcSEcCtD
Nelfinavir—Malnutrition—Epirubicin—bone cancer	0.000198	0.00233	CcSEcCtD
Nelfinavir—Erythema—Epirubicin—bone cancer	0.000198	0.00233	CcSEcCtD
Nelfinavir—Eye disorder—Doxorubicin—bone cancer	0.000197	0.00231	CcSEcCtD
Nelfinavir—Ill-defined disorder—Methotrexate—bone cancer	0.000197	0.00231	CcSEcCtD
Nelfinavir—Anaemia—Methotrexate—bone cancer	0.000196	0.0023	CcSEcCtD
Nelfinavir—Flatulence—Epirubicin—bone cancer	0.000195	0.00229	CcSEcCtD
Nelfinavir—Back pain—Epirubicin—bone cancer	0.000192	0.00225	CcSEcCtD
Nelfinavir—Angiopathy—Doxorubicin—bone cancer	0.000191	0.00224	CcSEcCtD
Nelfinavir—Malaise—Methotrexate—bone cancer	0.000191	0.00224	CcSEcCtD
Nelfinavir—Muscle spasms—Epirubicin—bone cancer	0.000191	0.00224	CcSEcCtD
Nelfinavir—Immune system disorder—Doxorubicin—bone cancer	0.00019	0.00223	CcSEcCtD
Nelfinavir—Leukopenia—Methotrexate—bone cancer	0.00019	0.00223	CcSEcCtD
Nelfinavir—Nausea—Cisplatin—bone cancer	0.000187	0.0022	CcSEcCtD
Nelfinavir—Ill-defined disorder—Epirubicin—bone cancer	0.000184	0.00216	CcSEcCtD
Nelfinavir—Convulsion—Methotrexate—bone cancer	0.000184	0.00215	CcSEcCtD
Nelfinavir—Malnutrition—Doxorubicin—bone cancer	0.000184	0.00215	CcSEcCtD
Nelfinavir—Erythema—Doxorubicin—bone cancer	0.000184	0.00215	CcSEcCtD
Nelfinavir—Anaemia—Epirubicin—bone cancer	0.000183	0.00215	CcSEcCtD
Nelfinavir—Agitation—Epirubicin—bone cancer	0.000182	0.00214	CcSEcCtD
Nelfinavir—Flatulence—Doxorubicin—bone cancer	0.000181	0.00212	CcSEcCtD
Nelfinavir—Myalgia—Methotrexate—bone cancer	0.00018	0.00212	CcSEcCtD
Nelfinavir—Arthralgia—Methotrexate—bone cancer	0.00018	0.00212	CcSEcCtD
Nelfinavir—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000179	0.00334	CbGpPWpGaD
Nelfinavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000179	0.0021	CcSEcCtD
Nelfinavir—Malaise—Epirubicin—bone cancer	0.000179	0.0021	CcSEcCtD
Nelfinavir—Discomfort—Methotrexate—bone cancer	0.000178	0.00209	CcSEcCtD
Nelfinavir—Leukopenia—Epirubicin—bone cancer	0.000178	0.00208	CcSEcCtD
Nelfinavir—Back pain—Doxorubicin—bone cancer	0.000178	0.00208	CcSEcCtD
Nelfinavir—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000177	0.0033	CbGpPWpGaD
Nelfinavir—Muscle spasms—Doxorubicin—bone cancer	0.000176	0.00207	CcSEcCtD
Nelfinavir—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000175	0.00327	CbGpPWpGaD
Nelfinavir—Convulsion—Epirubicin—bone cancer	0.000172	0.00202	CcSEcCtD
Nelfinavir—Ill-defined disorder—Doxorubicin—bone cancer	0.00017	0.002	CcSEcCtD
Nelfinavir—Anaemia—Doxorubicin—bone cancer	0.00017	0.00199	CcSEcCtD
Nelfinavir—Thrombocytopenia—Methotrexate—bone cancer	0.000169	0.00199	CcSEcCtD
Nelfinavir—Myalgia—Epirubicin—bone cancer	0.000169	0.00198	CcSEcCtD
Nelfinavir—Arthralgia—Epirubicin—bone cancer	0.000169	0.00198	CcSEcCtD
Nelfinavir—Agitation—Doxorubicin—bone cancer	0.000169	0.00198	CcSEcCtD
Nelfinavir—Anxiety—Epirubicin—bone cancer	0.000168	0.00197	CcSEcCtD
Nelfinavir—Skin disorder—Methotrexate—bone cancer	0.000168	0.00197	CcSEcCtD
Nelfinavir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000168	0.00197	CcSEcCtD
Nelfinavir—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000167	0.00311	CbGpPWpGaD
Nelfinavir—Hyperhidrosis—Methotrexate—bone cancer	0.000167	0.00196	CcSEcCtD
Nelfinavir—Discomfort—Epirubicin—bone cancer	0.000167	0.00196	CcSEcCtD
Nelfinavir—Malaise—Doxorubicin—bone cancer	0.000166	0.00194	CcSEcCtD
Nelfinavir—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000165	0.00307	CbGpPWpGaD
Nelfinavir—Anorexia—Methotrexate—bone cancer	0.000165	0.00193	CcSEcCtD
Nelfinavir—Leukopenia—Doxorubicin—bone cancer	0.000164	0.00193	CcSEcCtD
Nelfinavir—Oedema—Epirubicin—bone cancer	0.000162	0.0019	CcSEcCtD
Nelfinavir—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000161	0.003	CbGpPWpGaD
Nelfinavir—Convulsion—Doxorubicin—bone cancer	0.000159	0.00187	CcSEcCtD
Nelfinavir—Thrombocytopenia—Epirubicin—bone cancer	0.000158	0.00186	CcSEcCtD
Nelfinavir—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000158	0.00185	CcSEcCtD
Nelfinavir—Skin disorder—Epirubicin—bone cancer	0.000157	0.00185	CcSEcCtD
Nelfinavir—Hyperhidrosis—Epirubicin—bone cancer	0.000156	0.00184	CcSEcCtD
Nelfinavir—Insomnia—Methotrexate—bone cancer	0.000156	0.00184	CcSEcCtD
Nelfinavir—Arthralgia—Doxorubicin—bone cancer	0.000156	0.00183	CcSEcCtD
Nelfinavir—Myalgia—Doxorubicin—bone cancer	0.000156	0.00183	CcSEcCtD
Nelfinavir—Anxiety—Doxorubicin—bone cancer	0.000156	0.00183	CcSEcCtD
Nelfinavir—Paraesthesia—Methotrexate—bone cancer	0.000155	0.00182	CcSEcCtD
Nelfinavir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000155	0.00182	CcSEcCtD
Nelfinavir—Discomfort—Doxorubicin—bone cancer	0.000154	0.00181	CcSEcCtD
Nelfinavir—Anorexia—Epirubicin—bone cancer	0.000154	0.00181	CcSEcCtD
Nelfinavir—Dyspnoea—Methotrexate—bone cancer	0.000154	0.00181	CcSEcCtD
Nelfinavir—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000154	0.00286	CbGpPWpGaD
Nelfinavir—Somnolence—Methotrexate—bone cancer	0.000154	0.0018	CcSEcCtD
Nelfinavir—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000152	0.00284	CbGpPWpGaD
Nelfinavir—Dyspepsia—Methotrexate—bone cancer	0.000152	0.00179	CcSEcCtD
Nelfinavir—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000152	0.00283	CbGpPWpGaD
Nelfinavir—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00015	0.0028	CbGpPWpGaD
Nelfinavir—Decreased appetite—Methotrexate—bone cancer	0.00015	0.00176	CcSEcCtD
Nelfinavir—Oedema—Doxorubicin—bone cancer	0.00015	0.00176	CcSEcCtD
Nelfinavir—Gastrointestinal disorder—Methotrexate—bone cancer	0.000149	0.00175	CcSEcCtD
Nelfinavir—Pain—Methotrexate—bone cancer	0.000148	0.00174	CcSEcCtD
Nelfinavir—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000147	0.00173	CcSEcCtD
Nelfinavir—Thrombocytopenia—Doxorubicin—bone cancer	0.000147	0.00172	CcSEcCtD
Nelfinavir—Insomnia—Epirubicin—bone cancer	0.000146	0.00172	CcSEcCtD
Nelfinavir—Skin disorder—Doxorubicin—bone cancer	0.000145	0.00171	CcSEcCtD
Nelfinavir—Paraesthesia—Epirubicin—bone cancer	0.000145	0.00171	CcSEcCtD
Nelfinavir—Hyperhidrosis—Doxorubicin—bone cancer	0.000145	0.0017	CcSEcCtD
Nelfinavir—Dyspnoea—Epirubicin—bone cancer	0.000144	0.00169	CcSEcCtD
Nelfinavir—Somnolence—Epirubicin—bone cancer	0.000144	0.00169	CcSEcCtD
Nelfinavir—Anorexia—Doxorubicin—bone cancer	0.000143	0.00168	CcSEcCtD
Nelfinavir—Feeling abnormal—Methotrexate—bone cancer	0.000143	0.00167	CcSEcCtD
Nelfinavir—Dyspepsia—Epirubicin—bone cancer	0.000142	0.00167	CcSEcCtD
Nelfinavir—Gastrointestinal pain—Methotrexate—bone cancer	0.000141	0.00166	CcSEcCtD
Nelfinavir—Decreased appetite—Epirubicin—bone cancer	0.000141	0.00165	CcSEcCtD
Nelfinavir—Gastrointestinal disorder—Epirubicin—bone cancer	0.00014	0.00164	CcSEcCtD
Nelfinavir—Pain—Epirubicin—bone cancer	0.000138	0.00162	CcSEcCtD
Nelfinavir—Urticaria—Methotrexate—bone cancer	0.000137	0.00161	CcSEcCtD
Nelfinavir—Body temperature increased—Methotrexate—bone cancer	0.000137	0.0016	CcSEcCtD
Nelfinavir—Abdominal pain—Methotrexate—bone cancer	0.000137	0.0016	CcSEcCtD
Nelfinavir—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000136	0.0016	CcSEcCtD
Nelfinavir—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000136	0.00253	CbGpPWpGaD
Nelfinavir—Insomnia—Doxorubicin—bone cancer	0.000135	0.00159	CcSEcCtD
Nelfinavir—Paraesthesia—Doxorubicin—bone cancer	0.000134	0.00158	CcSEcCtD
Nelfinavir—Dyspnoea—Doxorubicin—bone cancer	0.000134	0.00157	CcSEcCtD
Nelfinavir—Feeling abnormal—Epirubicin—bone cancer	0.000133	0.00157	CcSEcCtD
Nelfinavir—Somnolence—Doxorubicin—bone cancer	0.000133	0.00156	CcSEcCtD
Nelfinavir—Gastrointestinal pain—Epirubicin—bone cancer	0.000132	0.00155	CcSEcCtD
Nelfinavir—Dyspepsia—Doxorubicin—bone cancer	0.000132	0.00155	CcSEcCtD
Nelfinavir—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00013	0.00243	CbGpPWpGaD
Nelfinavir—Decreased appetite—Doxorubicin—bone cancer	0.00013	0.00153	CcSEcCtD
Nelfinavir—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000129	0.00152	CcSEcCtD
Nelfinavir—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000129	0.0024	CbGpPWpGaD
Nelfinavir—Urticaria—Epirubicin—bone cancer	0.000129	0.00151	CcSEcCtD
Nelfinavir—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000129	0.0024	CbGpPWpGaD
Nelfinavir—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	0.000128	0.00239	CbGpPWpGaD
Nelfinavir—Pain—Doxorubicin—bone cancer	0.000128	0.0015	CcSEcCtD
Nelfinavir—Abdominal pain—Epirubicin—bone cancer	0.000128	0.0015	CcSEcCtD
Nelfinavir—Body temperature increased—Epirubicin—bone cancer	0.000128	0.0015	CcSEcCtD
Nelfinavir—Hypersensitivity—Methotrexate—bone cancer	0.000127	0.0015	CcSEcCtD
Nelfinavir—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000127	0.00237	CbGpPWpGaD
Nelfinavir—SLCO1A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000126	0.00234	CbGpPWpGaD
Nelfinavir—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000125	0.00232	CbGpPWpGaD
Nelfinavir—Asthenia—Methotrexate—bone cancer	0.000124	0.00146	CcSEcCtD
Nelfinavir—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000124	0.0023	CbGpPWpGaD
Nelfinavir—Feeling abnormal—Doxorubicin—bone cancer	0.000123	0.00145	CcSEcCtD
Nelfinavir—Gastrointestinal pain—Doxorubicin—bone cancer	0.000122	0.00144	CcSEcCtD
Nelfinavir—Pruritus—Methotrexate—bone cancer	0.000122	0.00144	CcSEcCtD
Nelfinavir—Hypersensitivity—Epirubicin—bone cancer	0.000119	0.0014	CcSEcCtD
Nelfinavir—Urticaria—Doxorubicin—bone cancer	0.000119	0.0014	CcSEcCtD
Nelfinavir—Abdominal pain—Doxorubicin—bone cancer	0.000118	0.00139	CcSEcCtD
Nelfinavir—Body temperature increased—Doxorubicin—bone cancer	0.000118	0.00139	CcSEcCtD
Nelfinavir—Diarrhoea—Methotrexate—bone cancer	0.000118	0.00139	CcSEcCtD
Nelfinavir—Asthenia—Epirubicin—bone cancer	0.000116	0.00136	CcSEcCtD
Nelfinavir—Pruritus—Epirubicin—bone cancer	0.000115	0.00134	CcSEcCtD
Nelfinavir—Dizziness—Methotrexate—bone cancer	0.000114	0.00134	CcSEcCtD
Nelfinavir—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000112	0.00209	CbGpPWpGaD
Nelfinavir—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000112	0.00208	CbGpPWpGaD
Nelfinavir—Diarrhoea—Epirubicin—bone cancer	0.000111	0.0013	CcSEcCtD
Nelfinavir—Hypersensitivity—Doxorubicin—bone cancer	0.00011	0.00129	CcSEcCtD
Nelfinavir—CYP3A7—Biological oxidations—GSTP1—bone cancer	0.00011	0.00205	CbGpPWpGaD
Nelfinavir—Vomiting—Methotrexate—bone cancer	0.00011	0.00129	CcSEcCtD
Nelfinavir—Rash—Methotrexate—bone cancer	0.000109	0.00128	CcSEcCtD
Nelfinavir—Dermatitis—Methotrexate—bone cancer	0.000109	0.00128	CcSEcCtD
Nelfinavir—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	0.000109	0.00202	CbGpPWpGaD
Nelfinavir—SLCO1A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000109	0.00202	CbGpPWpGaD
Nelfinavir—Headache—Methotrexate—bone cancer	0.000108	0.00127	CcSEcCtD
Nelfinavir—SLCO1B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000108	0.00201	CbGpPWpGaD
Nelfinavir—Asthenia—Doxorubicin—bone cancer	0.000107	0.00126	CcSEcCtD
Nelfinavir—Dizziness—Epirubicin—bone cancer	0.000107	0.00126	CcSEcCtD
Nelfinavir—Pruritus—Doxorubicin—bone cancer	0.000106	0.00124	CcSEcCtD
Nelfinavir—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000106	0.00197	CbGpPWpGaD
Nelfinavir—Vomiting—Epirubicin—bone cancer	0.000103	0.00121	CcSEcCtD
Nelfinavir—Nausea—Methotrexate—bone cancer	0.000103	0.00121	CcSEcCtD
Nelfinavir—Diarrhoea—Doxorubicin—bone cancer	0.000102	0.0012	CcSEcCtD
Nelfinavir—Rash—Epirubicin—bone cancer	0.000102	0.0012	CcSEcCtD
Nelfinavir—Dermatitis—Epirubicin—bone cancer	0.000102	0.0012	CcSEcCtD
Nelfinavir—Headache—Epirubicin—bone cancer	0.000101	0.00119	CcSEcCtD
Nelfinavir—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.97e-05	0.00186	CbGpPWpGaD
Nelfinavir—Dizziness—Doxorubicin—bone cancer	9.9e-05	0.00116	CcSEcCtD
Nelfinavir—SLCO1A2—Metabolism—NDUFA12—bone cancer	9.84e-05	0.00183	CbGpPWpGaD
Nelfinavir—Nausea—Epirubicin—bone cancer	9.62e-05	0.00113	CcSEcCtD
Nelfinavir—CYP2B6—Biological oxidations—CYP3A4—bone cancer	9.53e-05	0.00178	CbGpPWpGaD
Nelfinavir—Vomiting—Doxorubicin—bone cancer	9.52e-05	0.00112	CcSEcCtD
Nelfinavir—Rash—Doxorubicin—bone cancer	9.44e-05	0.00111	CcSEcCtD
Nelfinavir—Dermatitis—Doxorubicin—bone cancer	9.44e-05	0.00111	CcSEcCtD
Nelfinavir—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	9.4e-05	0.00175	CbGpPWpGaD
Nelfinavir—Headache—Doxorubicin—bone cancer	9.38e-05	0.0011	CcSEcCtD
Nelfinavir—CYP3A5—Biological oxidations—CYP3A4—bone cancer	9.32e-05	0.00174	CbGpPWpGaD
Nelfinavir—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.29e-05	0.00173	CbGpPWpGaD
Nelfinavir—SLC22A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.19e-05	0.00171	CbGpPWpGaD
Nelfinavir—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	9.19e-05	0.00171	CbGpPWpGaD
Nelfinavir—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	9.17e-05	0.00171	CbGpPWpGaD
Nelfinavir—Nausea—Doxorubicin—bone cancer	8.9e-05	0.00104	CcSEcCtD
Nelfinavir—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	8.69e-05	0.00162	CbGpPWpGaD
Nelfinavir—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.6e-05	0.0016	CbGpPWpGaD
Nelfinavir—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	8.57e-05	0.0016	CbGpPWpGaD
Nelfinavir—SLCO1B1—Metabolism—NDUFA12—bone cancer	8.42e-05	0.00157	CbGpPWpGaD
Nelfinavir—CYP1A2—Phase II conjugation—GSTP1—bone cancer	8.2e-05	0.00153	CbGpPWpGaD
Nelfinavir—SLCO1A2—Metabolism—NT5C3A—bone cancer	8.16e-05	0.00152	CbGpPWpGaD
Nelfinavir—CYP2B6—Biological oxidations—GSTP1—bone cancer	8.15e-05	0.00152	CbGpPWpGaD
Nelfinavir—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	8.04e-05	0.0015	CbGpPWpGaD
Nelfinavir—CYP3A5—Biological oxidations—GSTP1—bone cancer	7.97e-05	0.00148	CbGpPWpGaD
Nelfinavir—SLC22A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.94e-05	0.00148	CbGpPWpGaD
Nelfinavir—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	7.86e-05	0.00146	CbGpPWpGaD
Nelfinavir—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	7.82e-05	0.00146	CbGpPWpGaD
Nelfinavir—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	7.8e-05	0.00145	CbGpPWpGaD
Nelfinavir—ABCG2—Metabolism—NDUFA12—bone cancer	7.79e-05	0.00145	CbGpPWpGaD
Nelfinavir—CYP3A7—Metabolism—NDUFA12—bone cancer	7.72e-05	0.00144	CbGpPWpGaD
Nelfinavir—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	7.41e-05	0.00138	CbGpPWpGaD
Nelfinavir—CYP2C19—Biological oxidations—CYP3A4—bone cancer	7.2e-05	0.00134	CbGpPWpGaD
Nelfinavir—SLC22A1—Metabolism—NDUFA12—bone cancer	7.19e-05	0.00134	CbGpPWpGaD
Nelfinavir—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	7.14e-05	0.00133	CbGpPWpGaD
Nelfinavir—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	7.1e-05	0.00132	CbGpPWpGaD
Nelfinavir—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	7.1e-05	0.00132	CbGpPWpGaD
Nelfinavir—SLCO1B1—Metabolism—NT5C3A—bone cancer	6.97e-05	0.0013	CbGpPWpGaD
Nelfinavir—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	6.68e-05	0.00124	CbGpPWpGaD
Nelfinavir—CYP2D6—Biological oxidations—CYP3A4—bone cancer	6.62e-05	0.00123	CbGpPWpGaD
Nelfinavir—CYP2C9—Biological oxidations—CYP3A4—bone cancer	6.57e-05	0.00122	CbGpPWpGaD
Nelfinavir—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	6.53e-05	0.00122	CbGpPWpGaD
Nelfinavir—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	6.48e-05	0.00121	CbGpPWpGaD
Nelfinavir—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	6.46e-05	0.0012	CbGpPWpGaD
Nelfinavir—ABCG2—Metabolism—NT5C3A—bone cancer	6.46e-05	0.0012	CbGpPWpGaD
Nelfinavir—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	6.44e-05	0.0012	CbGpPWpGaD
Nelfinavir—CYP3A7—Metabolism—NT5C3A—bone cancer	6.4e-05	0.00119	CbGpPWpGaD
Nelfinavir—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	6.38e-05	0.00119	CbGpPWpGaD
Nelfinavir—CYP2C19—Biological oxidations—GSTP1—bone cancer	6.16e-05	0.00115	CbGpPWpGaD
Nelfinavir—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	6.07e-05	0.00113	CbGpPWpGaD
Nelfinavir—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	6.04e-05	0.00113	CbGpPWpGaD
Nelfinavir—SLC22A1—Metabolism—NT5C3A—bone cancer	5.96e-05	0.00111	CbGpPWpGaD
Nelfinavir—SLC22A1—Transmission across Chemical Synapses—BRAF—bone cancer	5.83e-05	0.00109	CbGpPWpGaD
Nelfinavir—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	5.72e-05	0.00106	CbGpPWpGaD
Nelfinavir—CYP2B6—Metabolism—NDUFA12—bone cancer	5.71e-05	0.00106	CbGpPWpGaD
Nelfinavir—CYP2D6—Biological oxidations—GSTP1—bone cancer	5.67e-05	0.00106	CbGpPWpGaD
Nelfinavir—CYP2C9—Biological oxidations—GSTP1—bone cancer	5.62e-05	0.00105	CbGpPWpGaD
Nelfinavir—CYP1A2—Biological oxidations—CYP3A4—bone cancer	5.61e-05	0.00105	CbGpPWpGaD
Nelfinavir—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	5.59e-05	0.00104	CbGpPWpGaD
Nelfinavir—CYP3A5—Metabolism—NDUFA12—bone cancer	5.58e-05	0.00104	CbGpPWpGaD
Nelfinavir—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	5.54e-05	0.00103	CbGpPWpGaD
Nelfinavir—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	5.53e-05	0.00103	CbGpPWpGaD
Nelfinavir—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	5.4e-05	0.00101	CbGpPWpGaD
Nelfinavir—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	5.39e-05	0.001	CbGpPWpGaD
Nelfinavir—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	5.06e-05	0.000943	CbGpPWpGaD
Nelfinavir—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	5.06e-05	0.000943	CbGpPWpGaD
Nelfinavir—SLC22A1—Transmission across Chemical Synapses—MDM2—bone cancer	4.89e-05	0.00091	CbGpPWpGaD
Nelfinavir—CYP1A2—Biological oxidations—GSTP1—bone cancer	4.8e-05	0.000894	CbGpPWpGaD
Nelfinavir—CYP2B6—Metabolism—NT5C3A—bone cancer	4.73e-05	0.000882	CbGpPWpGaD
Nelfinavir—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	4.73e-05	0.000882	CbGpPWpGaD
Nelfinavir—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.65e-05	0.000866	CbGpPWpGaD
Nelfinavir—CYP3A5—Metabolism—NT5C3A—bone cancer	4.63e-05	0.000862	CbGpPWpGaD
Nelfinavir—SLC22A1—Neuronal System—BRAF—bone cancer	4.47e-05	0.000832	CbGpPWpGaD
Nelfinavir—CYP2C19—Metabolism—NDUFA12—bone cancer	4.32e-05	0.000804	CbGpPWpGaD
Nelfinavir—ABCB1—Metabolism—NDUFA12—bone cancer	4.21e-05	0.000785	CbGpPWpGaD
Nelfinavir—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	4.01e-05	0.000746	CbGpPWpGaD
Nelfinavir—CYP2D6—Metabolism—NDUFA12—bone cancer	3.97e-05	0.00074	CbGpPWpGaD
Nelfinavir—CYP2C9—Metabolism—NDUFA12—bone cancer	3.94e-05	0.000733	CbGpPWpGaD
Nelfinavir—SLC22A1—Neuronal System—MDM2—bone cancer	3.74e-05	0.000697	CbGpPWpGaD
Nelfinavir—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.7e-05	0.00069	CbGpPWpGaD
Nelfinavir—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.65e-05	0.00068	CbGpPWpGaD
Nelfinavir—CYP2C19—Metabolism—NT5C3A—bone cancer	3.58e-05	0.000666	CbGpPWpGaD
Nelfinavir—SLCO1A2—Metabolism—ENO2—bone cancer	3.57e-05	0.000665	CbGpPWpGaD
Nelfinavir—ABCB1—Metabolism—NT5C3A—bone cancer	3.49e-05	0.00065	CbGpPWpGaD
Nelfinavir—CYP1A2—Metabolism—NDUFA12—bone cancer	3.36e-05	0.000626	CbGpPWpGaD
Nelfinavir—SLCO1A2—Metabolism—DHFR—bone cancer	3.31e-05	0.000617	CbGpPWpGaD
Nelfinavir—CYP2D6—Metabolism—NT5C3A—bone cancer	3.29e-05	0.000613	CbGpPWpGaD
Nelfinavir—CYP2C9—Metabolism—NT5C3A—bone cancer	3.26e-05	0.000607	CbGpPWpGaD
Nelfinavir—SLCO1A2—Metabolism—GNA11—bone cancer	3.1e-05	0.000577	CbGpPWpGaD
Nelfinavir—SLCO1B1—Metabolism—ENO2—bone cancer	3.05e-05	0.000569	CbGpPWpGaD
Nelfinavir—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.97e-05	0.000553	CbGpPWpGaD
Nelfinavir—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.86e-05	0.000533	CbGpPWpGaD
Nelfinavir—SLCO1B1—Metabolism—DHFR—bone cancer	2.83e-05	0.000528	CbGpPWpGaD
Nelfinavir—ABCG2—Metabolism—ENO2—bone cancer	2.83e-05	0.000527	CbGpPWpGaD
Nelfinavir—SLCO1A2—Metabolism—CYP3A4—bone cancer	2.81e-05	0.000523	CbGpPWpGaD
Nelfinavir—CYP3A7—Metabolism—ENO2—bone cancer	2.8e-05	0.000522	CbGpPWpGaD
Nelfinavir—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.79e-05	0.00052	CbGpPWpGaD
Nelfinavir—CYP1A2—Metabolism—NT5C3A—bone cancer	2.79e-05	0.000519	CbGpPWpGaD
Nelfinavir—SLCO1B1—Metabolism—GNA11—bone cancer	2.65e-05	0.000493	CbGpPWpGaD
Nelfinavir—ABCG2—Metabolism—DHFR—bone cancer	2.62e-05	0.000489	CbGpPWpGaD
Nelfinavir—SLC22A1—Metabolism—ENO2—bone cancer	2.61e-05	0.000486	CbGpPWpGaD
Nelfinavir—CYP3A7—Metabolism—DHFR—bone cancer	2.6e-05	0.000484	CbGpPWpGaD
Nelfinavir—CYP3A4—Metabolism—NDUFA12—bone cancer	2.6e-05	0.000483	CbGpPWpGaD
Nelfinavir—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.58e-05	0.000481	CbGpPWpGaD
Nelfinavir—ABCG2—Metabolism—GNA11—bone cancer	2.45e-05	0.000457	CbGpPWpGaD
Nelfinavir—CYP3A7—Metabolism—GNA11—bone cancer	2.43e-05	0.000453	CbGpPWpGaD
Nelfinavir—SLC22A1—Metabolism—DHFR—bone cancer	2.42e-05	0.000451	CbGpPWpGaD
Nelfinavir—SLCO1A2—Metabolism—GSTP1—bone cancer	2.4e-05	0.000447	CbGpPWpGaD
Nelfinavir—SLCO1B1—Metabolism—CYP3A4—bone cancer	2.4e-05	0.000447	CbGpPWpGaD
Nelfinavir—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.39e-05	0.000445	CbGpPWpGaD
Nelfinavir—SLC22A1—Metabolism—GNA11—bone cancer	2.26e-05	0.000421	CbGpPWpGaD
Nelfinavir—ABCG2—Metabolism—CYP3A4—bone cancer	2.22e-05	0.000414	CbGpPWpGaD
Nelfinavir—CYP3A7—Metabolism—CYP3A4—bone cancer	2.2e-05	0.00041	CbGpPWpGaD
Nelfinavir—CYP3A4—Metabolism—NT5C3A—bone cancer	2.15e-05	0.000401	CbGpPWpGaD
Nelfinavir—CYP2B6—Metabolism—ENO2—bone cancer	2.07e-05	0.000386	CbGpPWpGaD
Nelfinavir—SLCO1B1—Metabolism—GSTP1—bone cancer	2.05e-05	0.000383	CbGpPWpGaD
Nelfinavir—SLC22A1—Metabolism—CYP3A4—bone cancer	2.05e-05	0.000382	CbGpPWpGaD
Nelfinavir—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.03e-05	0.000378	CbGpPWpGaD
Nelfinavir—CYP3A5—Metabolism—ENO2—bone cancer	2.03e-05	0.000377	CbGpPWpGaD
Nelfinavir—CYP2B6—Metabolism—DHFR—bone cancer	1.92e-05	0.000358	CbGpPWpGaD
Nelfinavir—ABCG2—Metabolism—GSTP1—bone cancer	1.9e-05	0.000354	CbGpPWpGaD
Nelfinavir—CYP3A7—Metabolism—GSTP1—bone cancer	1.88e-05	0.000351	CbGpPWpGaD
Nelfinavir—CYP3A5—Metabolism—DHFR—bone cancer	1.88e-05	0.00035	CbGpPWpGaD
Nelfinavir—CYP2B6—Metabolism—GNA11—bone cancer	1.8e-05	0.000335	CbGpPWpGaD
Nelfinavir—CYP3A5—Metabolism—GNA11—bone cancer	1.76e-05	0.000327	CbGpPWpGaD
Nelfinavir—SLC22A1—Metabolism—GSTP1—bone cancer	1.75e-05	0.000327	CbGpPWpGaD
Nelfinavir—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.7e-05	0.000318	CbGpPWpGaD
Nelfinavir—CYP2B6—Metabolism—CYP3A4—bone cancer	1.63e-05	0.000304	CbGpPWpGaD
Nelfinavir—CYP3A5—Metabolism—CYP3A4—bone cancer	1.59e-05	0.000297	CbGpPWpGaD
Nelfinavir—CYP2C19—Metabolism—ENO2—bone cancer	1.57e-05	0.000292	CbGpPWpGaD
Nelfinavir—ABCB1—Metabolism—ENO2—bone cancer	1.53e-05	0.000285	CbGpPWpGaD
Nelfinavir—CYP2C19—Metabolism—DHFR—bone cancer	1.45e-05	0.000271	CbGpPWpGaD
Nelfinavir—CYP2D6—Metabolism—ENO2—bone cancer	1.44e-05	0.000268	CbGpPWpGaD
Nelfinavir—CYP2C9—Metabolism—ENO2—bone cancer	1.43e-05	0.000266	CbGpPWpGaD
Nelfinavir—ABCB1—Metabolism—DHFR—bone cancer	1.42e-05	0.000264	CbGpPWpGaD
Nelfinavir—CYP2B6—Metabolism—GSTP1—bone cancer	1.39e-05	0.00026	CbGpPWpGaD
Nelfinavir—CYP3A5—Metabolism—GSTP1—bone cancer	1.36e-05	0.000254	CbGpPWpGaD
Nelfinavir—CYP2C19—Metabolism—GNA11—bone cancer	1.36e-05	0.000253	CbGpPWpGaD
Nelfinavir—CYP2D6—Metabolism—DHFR—bone cancer	1.34e-05	0.000249	CbGpPWpGaD
Nelfinavir—ABCB1—Metabolism—GNA11—bone cancer	1.33e-05	0.000247	CbGpPWpGaD
Nelfinavir—CYP2C9—Metabolism—DHFR—bone cancer	1.33e-05	0.000247	CbGpPWpGaD
Nelfinavir—CYP2D6—Metabolism—GNA11—bone cancer	1.25e-05	0.000233	CbGpPWpGaD
Nelfinavir—SLCO1A2—Metabolism—PTGS2—bone cancer	1.24e-05	0.000232	CbGpPWpGaD
Nelfinavir—CYP2C9—Metabolism—GNA11—bone cancer	1.24e-05	0.000231	CbGpPWpGaD
Nelfinavir—CYP2C19—Metabolism—CYP3A4—bone cancer	1.23e-05	0.000229	CbGpPWpGaD
Nelfinavir—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.23e-05	0.000228	CbGpPWpGaD
Nelfinavir—CYP1A2—Metabolism—ENO2—bone cancer	1.22e-05	0.000227	CbGpPWpGaD
Nelfinavir—ABCB1—Metabolism—CYP3A4—bone cancer	1.2e-05	0.000224	CbGpPWpGaD
Nelfinavir—CYP2D6—Metabolism—CYP3A4—bone cancer	1.13e-05	0.000211	CbGpPWpGaD
Nelfinavir—CYP1A2—Metabolism—DHFR—bone cancer	1.13e-05	0.000211	CbGpPWpGaD
Nelfinavir—CYP2C9—Metabolism—CYP3A4—bone cancer	1.12e-05	0.000209	CbGpPWpGaD
Nelfinavir—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.12e-05	0.000208	CbGpPWpGaD
Nelfinavir—SLCO1B1—Metabolism—PTGS2—bone cancer	1.06e-05	0.000198	CbGpPWpGaD
Nelfinavir—CYP1A2—Metabolism—GNA11—bone cancer	1.06e-05	0.000197	CbGpPWpGaD
Nelfinavir—CYP2C19—Metabolism—GSTP1—bone cancer	1.05e-05	0.000196	CbGpPWpGaD
Nelfinavir—ABCB1—Metabolism—GSTP1—bone cancer	1.03e-05	0.000191	CbGpPWpGaD
Nelfinavir—ABCG2—Metabolism—PTGS2—bone cancer	9.85e-06	0.000183	CbGpPWpGaD
Nelfinavir—CYP3A7—Metabolism—PTGS2—bone cancer	9.76e-06	0.000182	CbGpPWpGaD
Nelfinavir—CYP2D6—Metabolism—GSTP1—bone cancer	9.69e-06	0.00018	CbGpPWpGaD
Nelfinavir—CYP2C9—Metabolism—GSTP1—bone cancer	9.6e-06	0.000179	CbGpPWpGaD
Nelfinavir—CYP1A2—Metabolism—CYP3A4—bone cancer	9.6e-06	0.000179	CbGpPWpGaD
Nelfinavir—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.55e-06	0.000178	CbGpPWpGaD
Nelfinavir—CYP3A4—Metabolism—ENO2—bone cancer	9.42e-06	0.000175	CbGpPWpGaD
Nelfinavir—SLC22A1—Metabolism—PTGS2—bone cancer	9.09e-06	0.000169	CbGpPWpGaD
Nelfinavir—CYP3A4—Metabolism—DHFR—bone cancer	8.74e-06	0.000163	CbGpPWpGaD
Nelfinavir—CYP1A2—Metabolism—GSTP1—bone cancer	8.21e-06	0.000153	CbGpPWpGaD
Nelfinavir—CYP3A4—Metabolism—GNA11—bone cancer	8.17e-06	0.000152	CbGpPWpGaD
Nelfinavir—CYP2B6—Metabolism—PTGS2—bone cancer	7.22e-06	0.000135	CbGpPWpGaD
Nelfinavir—CYP3A5—Metabolism—PTGS2—bone cancer	7.06e-06	0.000131	CbGpPWpGaD
Nelfinavir—CYP3A4—Metabolism—GSTP1—bone cancer	6.33e-06	0.000118	CbGpPWpGaD
Nelfinavir—CYP2C19—Metabolism—PTGS2—bone cancer	5.46e-06	0.000102	CbGpPWpGaD
Nelfinavir—ABCB1—Metabolism—PTGS2—bone cancer	5.33e-06	9.92e-05	CbGpPWpGaD
Nelfinavir—CYP2D6—Metabolism—PTGS2—bone cancer	5.02e-06	9.35e-05	CbGpPWpGaD
Nelfinavir—CYP2C9—Metabolism—PTGS2—bone cancer	4.98e-06	9.27e-05	CbGpPWpGaD
Nelfinavir—CYP1A2—Metabolism—PTGS2—bone cancer	4.25e-06	7.92e-05	CbGpPWpGaD
Nelfinavir—CYP3A4—Metabolism—PTGS2—bone cancer	3.28e-06	6.11e-05	CbGpPWpGaD
